Evidence map›Paper›PMID 30718803›Full record

Trial reportBone marrow transplantation2019

Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation.

Hidehiro Itonaga, Ken Ishiyama, Kazunari Aoki, Jun Aoki, Takayuki Ishikawa, Kazuteru Ohashi, Takayuki Fukuda, Yukiyasu Ozawa, Shuichi Ota, Naoyuki Uchida and 7 more

Open access · bronzeAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 1 country.

Hidehiro ItonagaDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan. itonaga-ngs@umin.ac.jp.ORCID http://orcid.org/0000-0003-1438-3623
Ken IshiyamaDepartment of Hematology, Kanazawa University Hospital, Kanazawa, Japan.ORCID http://orcid.org/0000-0002-6189-0620
Kazunari AokiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Jun AokiDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City General Hospital, Kobe, Japan.
Kazuteru OhashiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Takayuki FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Koji IwatoDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Yuju OhnoDepartment of Internal Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
Minoko TakanashiBlood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Yasushi MiyazakiDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Nagasaki University Hospital · JPHamanomachi Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPHiroshima University · JPJapanese Red Cross Society, Japan · JPKanagawa Prefectural Hospital Organization · JPKanazawa University Hospital · JPKitakyushu Municipal Medical Center · JPKobe City Medical Center General Hospital · JPKyoto University · JPSapporo Hokuyu Hospital · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPTokyo Metropolitan Komagome Hospital · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a nationwide retrospective study to evaluate the prognostic influence of +1, der(1;7)(q10;p10) [hereafter der(1;7)] and -7/del(7q) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for de novo myelodysplastic syndromes (MDS). In this database, 69 MDS patients with der(1;7), 75 with -7/del(7q), and 511 with normal karyotype (NK) underwent allo-HSCT at advanced disease status. The 3-year overall survival (OS) and cumulative incidence of relapse (CIR) were 50.4 and 19.4% for those with der(1;7), 36.2 and 38.4% for -7/del(7q), and 51.1 and 20.7% for NK, respectively. In the multivariate analysis, the presence of -7/del(7q) correlated with a significantly shorter OS (HR [95% CI], 1.38 [1.00-1.89]; P = 0.048) and higher CIR (HR, 2.11 [1.36-3.28]; P = 0.001) than those with NK. There were 23 patients with der(1;7), 29 with -7/del(7q), and 347 with NK who underwent allo-HSCT at early disease status. The 3-year OS and CIR were as follows: 47.3 and 9.5% for the der(1;7) group, 70.5 and 13.8% for -7/del(7q), and 70.9 and 5.6% for NK, respectively. No significant differences were observed in OS and CIR among three groups. The impact of the loss of chromosome 7q on OS and CIR may differ based on its type and disease status after allo-HSCT for MDS.

Indexed as

Chromosome DeletionHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesAdolescentAdultAgedAllograftsChromosomes, Human, Pair 7Disease-Free SurvivalFemaleHumansMaleMiddle AgedSurvival Rate

Identifiers

PMID30718803
OpenAlexW2911650399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.